161 related articles for article (PubMed ID: 23963705)
1. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis.
Hickey AJ; Misra A; Fourie PB
J Pharm Sci; 2013 Nov; 102(11):3900-7. PubMed ID: 23963705
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
4. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation.
Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
Eur J Pharm Biopharm; 2014 Jan; 86(1):23-30. PubMed ID: 24189498
[TBL] [Abstract][Full Text] [Related]
5. Single-use disposable dry powder inhalers for pulmonary drug delivery.
Friebel C; Steckel H
Expert Opin Drug Deliv; 2010 Dec; 7(12):1359-72. PubMed ID: 21080859
[TBL] [Abstract][Full Text] [Related]
6. Dry powder inhalers of antitubercular drugs.
Nainwal N; Sharma Y; Jakhmola V
Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
[TBL] [Abstract][Full Text] [Related]
7. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
Mehta P; Bothiraja C; Kadam S; Pawar A
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
[TBL] [Abstract][Full Text] [Related]
8. Inhaled drug therapy for treatment of tuberculosis.
Misra A; Hickey AJ; Rossi C; Borchard G; Terada H; Makino K; Fourie PB; Colombo P
Tuberculosis (Edinb); 2011 Jan; 91(1):71-81. PubMed ID: 20875771
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary drug delivery by powder aerosols.
Yang MY; Chan JG; Chan HK
J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
[TBL] [Abstract][Full Text] [Related]
10. Inhaled formulations and pulmonary drug delivery systems for respiratory infections.
Zhou QT; Leung SS; Tang P; Parumasivam T; Loh ZH; Chan HK
Adv Drug Deliv Rev; 2015 May; 85():83-99. PubMed ID: 25451137
[TBL] [Abstract][Full Text] [Related]
11. Back to the future: inhaled drug products.
Hickey AJ
J Pharm Sci; 2013 Apr; 102(4):1165-72. PubMed ID: 23381932
[TBL] [Abstract][Full Text] [Related]
12. How can we bring high drug doses to the lung?
Claus S; Weiler C; Schiewe J; Friess W
Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
[TBL] [Abstract][Full Text] [Related]
13. Formulation considerations for dry powder inhalers.
Cordts E; Steckel H
Ther Deliv; 2014 Jun; 5(6):675-89. PubMed ID: 25090281
[TBL] [Abstract][Full Text] [Related]
14. Advances in device and formulation technologies for pulmonary drug delivery.
Chan JG; Wong J; Zhou QT; Leung SS; Chan HK
AAPS PharmSciTech; 2014 Aug; 15(4):882-97. PubMed ID: 24728868
[TBL] [Abstract][Full Text] [Related]
15. The quest to deliver high-dose rifampicin: can the inhaled approach help?
Khadka P; Dummer J; Hill PC; Das SC
Expert Opin Drug Deliv; 2024; 21(1):31-44. PubMed ID: 38180078
[TBL] [Abstract][Full Text] [Related]
16. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
Patil TS; Deshpande AS; Deshpande S; Shende P
J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
[TBL] [Abstract][Full Text] [Related]
17. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
[TBL] [Abstract][Full Text] [Related]
18. Device factors affecting pulmonary delivery of dry powders.
Smutney CC; Grant M; Kinsey PS
Ther Deliv; 2013 Aug; 4(8):939-49. PubMed ID: 23919473
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.
Garcia-Contreras L; Sethuraman V; Kazantseva M; Godfrey V; Hickey AJ
J Antimicrob Chemother; 2006 Nov; 58(5):980-6. PubMed ID: 16971416
[TBL] [Abstract][Full Text] [Related]
20. Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization.
Heng D; Lee SH; Ng WK; Chan HK; Kwek JW; Tan RB
Int J Pharm; 2013 Aug; 452(1-2):194-200. PubMed ID: 23680726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
